TARA
NASDAQ · Biotechnology
Protara Therapeutic Inc
$5.21
-0.09 (-1.70%)
Open$5.30
Previous Close$5.30
Day High$5.40
Day Low$5.18
52W High$7.82
52W Low$2.77
Volume—
Avg Volume2.02M
Market Cap300.49M
P/E Ratio—
EPS$-1.43
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+349.9% upside
Current
$5.21
$5.21
Target
$23.44
$23.44
$15.10
$23.44 avg
$28.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 193.62M | 202.51M | 206.29M |
| Net Income | -27,587,371 | -28,749,471 | -33,771,699 |
| Profit Margin | -14.3% | -14.2% | -16.4% |
| EBITDA | -51,862,975 | -48,122,998 | -52,884,989 |
| Free Cash Flow | -39,587,712 | -47,283,878 | -36,549,207 |
| Rev Growth | +24.4% | +2.2% | +1.5% |
| Debt/Equity | 0.26 | 0.22 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |